Is avoiding trial-phase peptides like retatrutide actually smart advice?

What did @nirvdoesfitness actually say?

The creator's core argument is straightforward: retatrutide is still in clinical trials, long-term data beyond one to two years doesn't exist, and anyone claiming the drug has no long-term effects is, in their words, "completely lying." They also noted that the short-term side effects reported in studies are nausea and constipation, and that no long-term cardiac, hepatic, or cancer risks have been proven yet.

To be clear, this isn't a hype video. The creator is actively pushing back against people rushing to use an investigational drug. That's a more responsible stance than most peptide content on TikTok, where unverified "optimization" claims run unchecked. The framing is cautious and the conclusion is honest: we don't know what five or ten years looks like. That's not a scare tactic. That's just accurate.

Does the science back this up?

Yes, in most of the ways that count. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. As of 2024, it remains in Phase 2 and Phase 3 trials. The longest published human data comes from a 48-week Phase 2 trial.

Jastreboff et al. (2023, New England Journal of Medicine) published results from a 48-week randomized controlled trial of retatrutide in adults with obesity. The most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, and constipation. Serious adverse events were reported in roughly 8 to 10 percent of participants across dose groups. The creator's identification of nausea and constipation as the notable short-term side effects is broadly consistent with this data, though diarrhea and vomiting were actually more common in some cohorts and worth mentioning.

On the question of long-term cardiac and cancer risk, the creator is right that we lack the data. Rodent studies with GLP-1 receptor agonists have raised questions about thyroid C-cell tumors, and those signals haven't been fully resolved for newer triple agonists. That's not proof of harm, but it is an open question regulators are watching.

What did they get wrong (or right)?

The creator got the headline right but fumbled a few details. Calling nausea and constipation "two very rare side effects" is inaccurate. In the Jastreboff 2023 trial, nausea occurred in 45 to 60 percent of participants depending on dose. That is not rare. That is the most commonly reported adverse event in the trial. Calling it rare could cause someone to be genuinely unprepared for how common GI side effects are with this drug class.

The broader logic holds up though. The creator is correct that the absence of proven long-term harm is not evidence of safety. That's a distinction a lot of wellness influencers get backward. When they say "anyone telling you that there are no long-term effects are completely lying," they're making an epistemically sound point: absence of evidence is not evidence of absence, especially with a drug that has less than two years of human trial data published.

One omission worth flagging: the video makes no mention that retatrutide is not FDA approved and is not legally available for general use in the United States outside of clinical trials. That context matters.

What should you actually know?

Retatrutide is not approved for use. If someone is selling it to you as a peptide or offering it through a telehealth platform right now, that is not a legal prescription drug. The FDA has not cleared it. Phase 3 trials are ongoing, and approval timelines are speculative.

The GLP-1 and triple agonist drug class has shown real weight loss results in trials. The Jastreboff 2023 data showed up to 24 percent body weight reduction at 48 weeks in some dose groups. Those are meaningful numbers. But weight loss results from a trial don't translate into a green light on long-term safety, and no one should be treating 48-week data as a lifetime safety profile.

The creator's instinct to urge caution here is sound. The peptide and biohacking communities often treat trial-phase compounds as consumer products, which they are not. If retatrutide eventually clears regulatory review, the safety picture will be clearer. Until then, the creator's conclusion stands: we do not know what a decade of use looks like, and that uncertainty is real.